Levomethadon Aristo (Levomethadone Hydrochloride)

• Levomethadone, an opioid analgesic, acts on the central nervous system to control pain and manage opioid dependence.
• Severe chronic pain: delivers sustained opioid analgesia that lowers pain intensity and improves functional ability in adults with long‑standing severe pain conditions.
• Cancer‑related pain: offers potent analgesic effect to manage moderate to severe nociceptive and neuropathic pain associated with malignant tumors, enhancing quality of life.
• Opioid dependence treatment: reduces withdrawal signs and cravings, supporting stabilization during opioid substitution programs and facilitating transition to lower‑risk therapies.

• Levomethadone is the levorotatory isomer of methadone that selectively activates μ‑opioid receptors in the central nervous system. Binding to these G‑protein‑coupled receptors inhibits adenylate cyclase activity, reduces neuronal excitability, and diminishes transmission of nociceptive signals. The drug also exhibits antagonism at NMDA receptors, contributing to its analgesic and anti‑withdrawal properties. This results in decreased perception of pain and mitigation of opioid‑withdrawal phenomena, while the stereospecific activity limits some of the excitatory effects seen with the racemic mixture.

Levomethadon Aristo may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Constipation: reduced bowel motility leading to infrequent, hard stools.
• Nausea: feeling of sickness or urge to vomit.
• Drowsiness: increased sleepiness or difficulty staying awake.
• Dizziness: sensation of light‑headedness or imbalance.
• Dry mouth: decreased salivation causing oral dryness.
• Sweating: excessive perspiration unrelated to temperature.

Serious or Rare Side Effects

• Respiratory depression: slowed breathing that may become life‑threatening.
• QT prolongation: heart rhythm disturbance increasing risk of arrhythmia.
• Seizures: sudden uncontrolled electrical activity in the brain.
• Severe hypotension: marked drop in blood pressure causing faintness.
• Adrenal insufficiency: inadequate cortisol production leading to fatigue.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.

• Before prescribing Levomethadon Aristo, clinicians should consider several precautionary measures to minimize risk.
• Assess respiratory function: monitor breathing rate and oxygen saturation before and during therapy.
• Monitor cardiac conduction: obtain baseline ECG and watch for QT interval changes.
• Evaluate hepatic function: adjust dosing in patients with liver impairment.
• Screen for dependence risk: assess history of substance misuse before initiating treatment.
• Avoid use in known hypersensitivity: discontinue if allergic signs appear.
• Store at below 25°C: keep in original packaging, protect from moisture and light.

Levomethadon can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• CNS depressants (e.g., benzodiazepines, barbiturates): may cause profound respiratory depression.
• Other opioids: additive opioid effects increase risk of overdose.
• MAO inhibitors: can precipitate severe serotonin syndrome.
• QT‑prolonging agents (e.g., macrolide antibiotics): heighten risk of cardiac arrhythmias.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): raise levomethadone plasma concentrations.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin): may reduce drug levels and analgesic effect.
• Serotonergic drugs (e.g., SSRIs, SNRIs): potential for mild serotonin syndrome.
• Alcohol: enhances sedative effects and respiratory depression.
• Antihistamines: can increase drowsiness.
• Diuretics: may affect electrolyte balance influencing cardiac risk.